Administering GLP-1 and FGF21 in combination was not expected to pose a risk of hypoglycemia, as each respective agonist is believed to contain built-in safety mechanisms preventing dangerous dips in blood glucose. This evidence concerns the gene GLP1R and Hypoglycemia.